NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Psychiatric, ADHD |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 6 - 12 |
| Updated: | 1/19/2018 |
| Start Date: | July 2013 |
| End Date: | July 2014 |
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to
evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory
classroom study.
evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory
classroom study.
Inclusion Criteria:
- Currently being treated for ADHD
Exclusion Criteria:
- Other psychiatric diagnoses
- Significant cognitive impairment
- Chronic medical illnesses
- Structural cardiac defects
- Significant abnormal lab tests
- Taking disallowed medications
- Positive drug test
We found this trial at
4
sites
8043 Cooper Creek Boulevard
Suite 107
Bradenton, Florida 34201
Bradenton, Florida 34201
(941) 747-7900
Florida Clinical Research Center, LLC Led by Andrew J. Cutler, M.D., Florida Clinical Research Center,...
Click here to add this to my saved trials
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials